World's Best Scientists 2026 revealed!
Laurence Albiges

Laurence Albiges

D-Index & Metrics

Medicine

D-Index
83
Citations
38765
World Ranking
15375
National Ranking
495

Overview

Laurence Albiges is affiliated with the Institut Gustave Roussy in France and has contributed extensively to medical research, particularly in the field of oncology and renal cell carcinoma treatment. Their work spans multiple areas including cancer immunotherapy, molecular biology, and cancer genomics, reflecting a multidisciplinary approach to cancer research.

Their main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

More specifically, the subfields they have worked in are:

  • Pulmonary and Respiratory Medicine
  • Oncology
  • Molecular Biology
  • Cancer Research
  • Economics and Econometrics

The primary topics Laurence Albiges focuses on include:

  • Renal cell carcinoma treatment
  • Cancer Immunotherapy and Biomarkers
  • Renal and related cancers
  • Cancer Genomics and Diagnostics
  • Economic and Financial Impacts of Cancer
  • Bladder and Urothelial Cancer Treatments
  • Pancreatic and Hepatic Oncology Research

Laurence Albiges has co-authored with leading experts in the field, frequently collaborating with:

  • Toni K. Choueiri
  • Bernard Escudier
  • Gwénaëlle Gravis
  • Ronan Flippot
  • Brian I. Rini

The researcher publishes regularly in several prominent venues, including:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Urology
  • European Journal of Cancer
  • European Urology Oncology

Significant recent publications by Laurence Albiges include:

  • "Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial," 2020, ESMO Open
  • "European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update," 2022, European Urology

Other relevant notable papers in their field, although authored by collaborators, which are closely related to their research interests, include:

  • "Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial," 2020, Nature Medicine
  • "Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma," 2020, Annals of Oncology
  • "Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage," 2020, Science

Best Publications

  • Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

    Bertrand Routy;Bertrand Routy;Bertrand Routy;Lisa Derosa;Lisa Derosa;Lisa Derosa;Connie P. M. Duong;Connie P. M. Duong

  • Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

    Robert J. Motzer;Konstantin Penkov;John Haanen;Brian Rini

  • Renal cell carcinoma.

    James J. Hsieh;Mark P. Purdue;Sabina Signoretti;Charles Swanton

  • Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.

    W. Marston Linehan;Paul T. Spellman;Christopher J. Ricketts;Chad J. Creighton

  • Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

    Arnaud Méjean;Alain Ravaud;Simon Thezenas;Sandra Colas

  • Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

    L. Derosa;L. Derosa;L. Derosa;M.D. Hellmann;M.D. Hellmann;M. Spaziano;D. Halpenny

  • Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.

    Gwenaelle Gravis;Jean-Marie Boher;Florence Joly;Michel Soulié

  • Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

    Claire L. Vale;Sarah Burdett;Larysa H. M. Rydzewska;Laurence Albiges

  • Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.

    Laurence Albiges;Nizar M. Tannir;Mauricio Burotto;David McDermott;David McDermott

  • Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

    Y. Loriot;D. Bianchini;E. Ileana;S. Sandhu

  • Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.

    Robert J. Motzer;Paul B. Robbins;Thomas Powles;Laurence Albiges

  • Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.

    T.K. Choueiri;R.J. Motzer;B.I. Rini;J. Haanen

  • Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.

    Jean-Marie Michot;Laurence Albiges;Nathalie Chaput;Veronique Saada

  • Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage.

    Aurélie Fluckiger;Aurélie Fluckiger;Romain Daillère;Romain Daillère;Mohamed Sassi;Barbara Susanne Sixt

  • Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

    Nizar M. Tannir;Eric Jonasch;Laurence Albiges;Emre Altinmakas

  • PD-L1 expression in nonclear-cell renal cell carcinoma

    T. K. Choueiri;T. K. Choueiri;A. P. Fay;K. P. Gray;M. Callea

  • Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

    François-Xavier Danlos;Anne-Laure Voisin;Valérie Dyevre;Jean-Marie Michot

  • Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.

    Toni K. Choueiri;Mayer Fishman;Bernard Escudier;David F. McDermott

  • Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus.

    G. Curigliano;S. Banerjee;A. Cervantes;A. Cervantes;M.C. Garassino

  • Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

    Marcella Callea;Laurence Albiges;Mamta Gupta;Mamta Gupta;Su-Chun Cheng

Frequent Co-Authors

Bernard Escudier
Bernard Escudier Institut Gustave Roussy
Toni K. Choueiri
Toni K. Choueiri Harvard University
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Yohann Loriot
Yohann Loriot University of Paris-Saclay
Thomas Powles
Thomas Powles Queen Mary University of London
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Stéphane Oudard
Stéphane Oudard Hôpital Européen Georges-Pompidou
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Christine Chevreau
Christine Chevreau DuPont (United States)
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students exploring Medicine in the USA, there are a growing number of online degree options that can lead to rewarding healthcare careers. Online programs offer flexibility for working adults and those seeking to advance their education while balancing other commitments.

If you’re interested in healthcare leadership, consider enrolling in cheap mha programs to prepare for management positions. For nurses aiming to reach advanced practice or leadership roles, some of the cheapest bsn to dnp programs offer a direct, affordable pathway from a BSN to a Doctor of Nursing Practice degree.

Aspiring pharmacists now have more options as well. Many online pharmacy schools provide flexible, accredited doctorate programs that can be pursued from anywhere in the country. Meanwhile, those interested in the intersection of technology, data, and healthcare may want to explore online schools for health information management—a field that’s rapidly growing alongside electronic medical record adoption.

With these online healthcare degrees, students can access new career pathways in the medical field and make valuable contributions to the future of healthcare in the USA.

Best Scientists Citing Laurence Albiges

Trending Scientists